Tanya B. Dorff

TL;DR: The NCCN Guidelines for Prostate Cancer include recommendations regarding diagnosis, risk stratification and workup, treatment options for localized disease, and management of recurrent and advanced disease for clinicians who treat patients with prostate cancer.

TL;DR: The NCCN Guidelines for Prostate Cancer address staging and risk assessment after a prostate cancer diagnosis and include management options for localized, regional, and metastatic disease Recommendations for disease monitoring and treatment of recurrent disease are also included as mentioned in this paper.

TL;DR: In this paper, the authors assessed the PARP inhibitor talazoparib in metastatic castration-resistant prostate cancers with DNA damage response (DDR) alterations in genes involved directly or indirectly in homologous recombination repair (HRR).

TL;DR: This review highlights the growing evidence in support of androgen regulation of TMPRSS2 and ACE2 and the potential clinical implications of using androgen suppression to downregulate TMPR SS2 to target SARS-CoV-2 and its relevance in the context of prostate cancer management.

TL;DR: CDK12 mutations define an aggressive prostate cancer subgroup, with a high rate of metastases and short overall survival, and exploratory analysis supports using anti-programmed cell death protein 1 drugs early.